Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Cohen, P. A. et al. (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 154(2), pp. 441-448. (doi: 10.1016/j.ygyno.2019.04.679) (PMID:31118141)

[img]
Preview
Text
217570.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

718kB

Abstract

Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). Results: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P < 0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). Conclusions: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Tan, Dr Yun Yi and Glasspool, Dr Rosalind
Authors: Cohen, P. A., Powell, A., Böhm, S., Gilks, C. B., Stewart, C. J.R., Meniawy, T. M., Bulsara, M., Avril, S., Brockbank, E. C., Bosse, T., de Azevedo Focchi, G. R., Ganesan, R., Glasspool, R. M., Howitt, B. E., Kim, H.-S., Lee, J.-Y., Le, N. D., Lockley, M., Manchanda, R., Mandalia, T., McCluggage, W. G., McNeish, I., Midha, D., Srinivasan, R., Tan, Y. Y., van der Griend, R., Yunokawa, M., Zannoni, G. F., Singh, N., Aggarwal, S., Bronger, H., Brown, E. B., Buck, M., Bukhari, S. A., Coghlan, E., Cope, N., de Almeida, M. S., De Kroon, C. D., Dean, A., Devlin, M.-J., Ditzel, H. M., Drecoll, E., Ebata, T., Fagotti, A., Faruqi, A., Feeney, L., Gupta, K., Harley, I., Inzani, F., Jeyarajah, A. R., Koay, M.H. E., Kroep, J. R., Lee, J.-Y., Leung, Y., Lockley, M., Loft, A. R., MaGee, D., Manchanda, R., McKenna, S., Midha, D., Millan, D., Millar, J., Miller, R., Mohan, G. R., Mughal, S., Nicolau, S. M., Nevin, J., Oakley, A. S., Quigley, M., Rai, B., Rajwanshi, A., Salfinger, S. G., Scambia, G., Scatchard, K., Schmalfeldt, B., Simcock, B., Singh, P., Strickland, K. C., Suri, V., Syed, S., Sykes, P., Tamura, K., Tan, A., Tan, J., Thompson, E., Tinker, A. V., Trevisan, G., Uyeda, M. G. B. K., Vaughan, M. M., Weichert, W., Williams, A., Williams, S., Yoshida, H., and Zorzato, P. C.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Gynecologic Oncology
Publisher:Elsevier
ISSN:0090-8258
ISSN (Online):1095-6859
Published Online:19 May 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Gynecologic Oncology 154(2):441-448
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record